COLL - Collegium Pharmaceutical, Inc.
After hours:
| Previous Close | 21.38 |
| Open | 21.35 |
| Bid | 21.94 x 1000 |
| Ask | 22.61 x 1000 |
| Day's Range | 21.00 - 22.09 |
| 52 Week Range | 15.10 - 30.22 |
| Volume | |
| Avg. Volume | 327,895 |
| Market Cap | 759.01M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.60 |
GlobeNewswireCollegium to Participate in Jefferies Healthcare Conference
STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023. Details of the event are as follows:Fireside Chat Date and Time: Thursday, June 8, 2023, at 12:30 p.m. ET T
ZacksCollegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksCollegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Collegium Reports First Quarter 2023 Financial Results
– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today r
ZacksPacira (PCRX) Lags Q1 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Informa
- GlobeNewswire
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 18, 2023, at 2:15 p
ZacksCOLL vs. ZTS: Which Stock Should Value Investors Buy Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
ZacksPacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
- Thomson Reuters StreetEvents
Q4 2022 Collegium Pharmaceutical Inc Earnings Call
Q4 2022 Collegium Pharmaceutical Inc Earnings Call
ZacksCollegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial r
ZacksEsperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
- GlobeNewswire
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
Highlights 2022 environmental, social and governance achievementsSTOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report. The report reflects the Company’s long-standing commitment to operating with integrity, accountability and responsibility in all facets of its business while improving the health and
ZacksWill Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCollegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCOLL or ZTS: Which Is the Better Value Stock Right Now?
COLL vs. ZTS: Which Stock Is the Better Value Option?
- GlobeNewswire
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amoun
- GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Collegium also expects to grant the initial purchaser of the notes an option to purc
- GlobeNewswire
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
-Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a pivotal year for Collegium Pharmace
ZacksZacks.com featured highlights MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical
MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical have been highlighted in this Screen of The Week article.
Zacks5 Stocks With Recent Price Strength Amid January Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.
Simply Wall St.Collegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their decent 62% return over the last year
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
ZacksRelay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.